Cargando…

Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation

Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chelariu-Raicu, Anca, Piha-Paul, Sarina A., Chavez-MacGregor, Mariana, Johnson, Jason, Sawaya, Raymond, McAleer, Mary Frances, Nguyen, Alissa, Hartnett, Audrey, Tsimberidou, Apostolia M., Meric-Bernstam, Funda, Dumbrava, Ecaterina E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Innovative Healthcare Institute 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448731/ https://www.ncbi.nlm.nih.gov/pubmed/37637237 http://dx.doi.org/10.36401/JIPO-22-33

Ejemplares similares

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

Multidisciplinary Management of Ataxia Telangiectasia: Current Perspectives
por: McGrath-Morrow, Sharon A, et al.
Publicado: (2021)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia
por: Bhatt, Jayesh M., et al.
Publicado: (2015)

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
por: Dumbrava, Ecaterina E. Ileana, et al.
Publicado: (2019)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
por: Son, Ji, et al.
Publicado: (2023)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Myoclonus in Ataxia–Telangiectasia
por: Termsarasab, Pichet, et al.
Publicado: (2015)

Growth in ataxia telangiectasia
por: Natale, Valerie A. I., et al.
Publicado: (2021)

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
por: Wang, Zhijie, et al.
Publicado: (2017)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss
por: Owusu-Brackett, Nicci, et al.
Publicado: (2020)

Ataxia telangiectasia: Family management
por: Seshachalam, Arun, et al.
Publicado: (2010)

Ataxia-telangiectasia: future prospects
por: Chaudhary, Mohammed Wajid, et al.
Publicado: (2014)

Ataxia telangiectasia: a review
por: Rothblum-Oviatt, Cynthia, et al.
Publicado: (2016)

Correction to: Growth in ataxia telangiectasia
por: Natale, Valerie A. I., et al.
Publicado: (2021)

Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
por: Ileana Dumbrava, Ecaterina, et al.
Publicado: (2018)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
por: Subbiah, Vivek, et al.
Publicado: (2016)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Bladder Wall Telangiectasia in a Patient with Ataxia-Telangiectasia and How to Manage?
por: Aygün, Fatma Deniz, et al.
Publicado: (2015)

Experimental Antioxidant Therapy in Ataxia Telangiectasia
por: Reliene, Ramune, et al.
Publicado: (2008)

Treatment of Granulomas in Patients With Ataxia Telangiectasia
por: Woelke, Sandra, et al.
Publicado: (2018)

Dysarthria in children and adults with ataxia telangiectasia
por: Veenhuis, Stefanie J G, et al.
Publicado: (2021)

Ataxia Telangiectasia Presenting as Cervical Dystonia
por: LNU, Priyal, et al.
Publicado: (2022)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2g4r6k6aelk99mjih1nc4hs7ir